Supplementary downloadable tables

  • Table INF-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2004, (a) cases per million population and (b) number of cases

  • Table INF-5. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs among all cases with known risk factor

  • Table INF-6. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs among all notified cases with known risk factor

  • Table INF-7. Incidence studies of hepatitis C virus infection among injecting drug users in the EU

  • Table INF-8. Prevalence of HIV infection (percentage) among injecting drug users

  • Table INF-9. Prevalence of HIV infection (percentage) among injecting drug users under age 25

  • Table INF-10. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years)

  • Table INF-11. Prevalence of hepatitis C infection (percentage) among injecting drug users

  • Table INF-12. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25

  • Table INF-13. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years)

  • Table INF-14. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users

  • Table INF-15. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users